Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid

Kamenova, Petya

doi:10.14310/horm.2002.11191

Cited by 93 publications

(77 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was no significant difference observed between the groups with regards to Fasting plasma glucose, Fasting insulin level or HOMA-IR in contrary to previous findings by Kamenova [39] who found that a 4 weeks oral treatment with ALA, 600 mg twice daily, significantly increased peripheral insulin sensitivity in patients with DM2 to a level almost similar to that of subjects with normal glucose tolerance. When the effect on lipid abnormalities was assessed, results didn't show any advantage for the combination over lipid profile, though the efficacy of ALA on dyslipidemia was different in other studies [40].…”

Section: Discussioncontrasting

confidence: 99%

Comparative Study of Vitamin B Complex Combined with Alpha Lipoic Acid versus Vitamin B Complex in Treatment of Diabetic Polyneuropathy in Type 2 Diabetic Patients

Ma¹,

He²,

Sabri³

et al. 2017

Clin Exp Pharmacol

View full text Add to dashboard Cite

Objective: Diabetic Polyneuropathy (DPN) represents a major health problem as it increases morbidity affecting patients' quality of life. Vitamin B frequently is used for treating DPN. ALPHA Lipoic Acid (ALA) seems to delay or reverse DPN. The present study compared the effect of Vitamin B complex combined with ALA versus Vitamin B in treatment of DPN in Egyptian type 2 diabetic patients. Methods:Forty type 2 diabetic patients with DPN of whom twenty received once-daily oral doses of ALA (600 mg) in combination with Vitamin B complex and the other twenty only received vitamin B complex for 12 weeks. Patients were evaluated by Michigan Neuropathy Screening Instrument (MNSI) questionnaire and Nerve Conduction Studies (NCS). Blood samples were collected for determination of Insulin Resistance and lipid abnormalities. All the previous assessments were performed at baseline and at week 12.Results: There was a significant reduction after 12 weeks of supplementation in vitamin B complex plus Alpha Lipoic Acid (ALA) group using MNSI questionnaire (p=0.001) and not in vitamin B complex group. NCS demonstrated that 12 out of 16 patients in vitamin B complex plus ALA group showed improvement in at least one property measured compared with only 6 out of 16 in vitamin B complex group (p=0.0732). The influence of the combination on the progression of diabetes with regards to insulin resistance and lipid profile showed no advantage over Vitamin B complex alone. Conclusion:Combined therapy of DPN with ALA and Vitamin B complex, orally for 12 weeks improves the symptoms of neuropathy (MNSI) with a similar trend in NCS.

show abstract

Section: Discussioncontrasting

confidence: 99%

Comparative Study of Vitamin B Complex Combined with Alpha Lipoic Acid versus Vitamin B Complex in Treatment of Diabetic Polyneuropathy in Type 2 Diabetic Patients

Ma¹,

He²,

Sabri³

et al. 2017

Clin Exp Pharmacol

View full text Add to dashboard Cite

show abstract

“…Thus, ALA exerts a beneficial effect on the vascular abnormalities of diabetes polyneuropathy and leads to an improvement in peripheral nerve function. ALA also increases insulin sensitivity (32). So ALA should be considered as a good choice among pathogenetically oriented treatments of diabetic neuropathy.…”

Section: Discussionmentioning

confidence: 99%

THERAPY OF ENDOCRINE DISEASE: A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy

Han

Bai

Liu

et al. 2012

European Journal of Endocrinology

142

View full text Add to dashboard Cite

Objective: To evaluate the effects and safety of 300-600 mg a-lipoic acid (ALA) given i.v. for diabetic peripheral neuropathy (DPN). Methods: We searched the databases of Medline, Embase, and Cochrane central register of Controlled Trials and Chinese biological medicine for clinical trials of ALA in the treatment of DPN. Data were extracted to examine methodological quality and describe characteristics of studies. The primary outcomes were efficacy, median motor nerve conduction velocity (MNCV), median sensory nerve conduction velocity (SNCV), peroneal MNCV, and peroneal SNCV. Secondary outcomes were adverse events. Results: Fifteen randomized controlled trials met the inclusion criteria. The treatment group involved the administration of ALA 300-600 mg i.v. per day. And the control group used the same interventions except for ALA. Compared with the control group, nerve conduction velocities increased significantly in the treatment group. The weighted mean differences in nerve conduction velocities were 4.63 (95% confidence interval 3.58-5.67) for median MNCV, 3.17 (1.75-4.59) for median SNCV, 4.25 (2.78-5.72) for peroneal MNCV, and 3.65 (1.50-5.80) for peroneal SNCV in favor of the treatment group. The odds ratio in terms of efficacy was 4.03 (2.73-5.94) for ALA. Furthermore, no serious adverse events were observed during the treatment period. Conclusions:The results of this meta-analysis provide evidence that treatment with ALA (300-600 mg/day i.v. for 2-4 weeks) is safe and that the treatment can significantly improve both nerve conduction velocity and positive neuropathic symptoms. However, the evidence may not be strong because most of the studies included in this meta-analysis have poor methodological quality.

show abstract

“…In another study, the oral supplementation ALA (600 mg twice daily for 4 weeks) treatment which increases the plasma insulin sensitivity [34]. According to Packer et al, ALA is capable to scavenge ROS produced during the lipid peroxidation and guards the cell structure against damage.…”

Section: Alpha-lipoic Acidmentioning

confidence: 99%

A Review on Role of Antioxidants in Diabetes

Rajendiran

Packirisamy

Giribabu³

2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Diabetes mellitus is a chronic metabolic disease. Oxidative stress plays a major part in the pathogenesis of diabetes. Supplementation with antioxidants and the medicinal plants which possess antioxidants activity have been reported their hypoglycemic activity. The antioxidants are used to treat and reduce the complication of diabetes mellitus. The diet supplementations of antioxidants vitamins are beneficial in the treatment of diabetes. This review article was summarizing the role of antioxidants in diabetes mellitus.

show abstract

Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid

Cited by 93 publications

References 22 publications

Comparative Study of Vitamin B Complex Combined with Alpha Lipoic Acid versus Vitamin B Complex in Treatment of Diabetic Polyneuropathy in Type 2 Diabetic Patients

Comparative Study of Vitamin B Complex Combined with Alpha Lipoic Acid versus Vitamin B Complex in Treatment of Diabetic Polyneuropathy in Type 2 Diabetic Patients

THERAPY OF ENDOCRINE DISEASE: A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy

A Review on Role of Antioxidants in Diabetes

Contact Info

Product

Resources

About